Recro Pharma (NASDAQ:REPH) Posts Earnings Results, Misses Estimates By $0.06 EPS
Recro Pharma (NASDAQ:REPH) issued its quarterly earnings data on Friday. The specialty pharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.06), Fidelity Earnings reports. The firm had revenue of $25.26 million during the quarter, compared to the consensus estimate of $19.83 million.
REPH stock traded up $1.74 during mid-day trading on Friday, reaching $17.45. The company’s stock had a trading volume of 1,005,300 shares, compared to its average volume of 278,815. The business’s 50 day moving average price is $12.62 and its 200 day moving average price is $10.71. Recro Pharma has a 12 month low of $5.53 and a 12 month high of $17.86. The company has a market cap of $366.69 million, a price-to-earnings ratio of -7.01 and a beta of -0.40.
REPH has been the subject of a number of analyst reports. Stephens initiated coverage on Recro Pharma in a research report on Wednesday, October 16th. They set an “overweight” rating and a $14.00 price objective for the company. Zacks Investment Research upgraded Recro Pharma from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a report on Wednesday, October 30th. BidaskClub upgraded Recro Pharma from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. Oppenheimer set a $20.00 target price on Recro Pharma and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, ValuEngine downgraded Recro Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Recro Pharma has an average rating of “Buy” and an average price target of $13.90.
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Recommended Story: High-Yield Dividend Stocks
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.